Amsterdam-based NLC Health Ventures, in collaboration with Verily (an Alphabet Inc. company formerly known as Google LifeSciences), on Monday announced the launch of Exolvo Biosciences, a biotech company delivering solutions for biologic drug delivery.
Through Exolvo, NLC seeks to advance drug delivery technology that was incubated within Verily and is now being spun out as a stand-alone private early-stage venture under NLC.
Exolvo’s oral drug delivery technology is distinguished by its flexible capsule size and modular design, allowing adaptation to a variety of large molecular structures.
“This technology has tremendous potential for significant impact. For patients, it means an improved and better treatment experience, and for healthcare workers, it simplifies administration and enhances efficiency in delivering care,” says Nick Ibery, UK Lead Partner at NLC.
The Need for Exolvo Biosciences
Biologic drugs are critical for treating chronic conditions, but their size and complexity make oral delivery challenging.
As a result, biologic drugs are usually administered through frequent and painful needle injections or intravenous administration.
Such treatments can be burdensome for patients and costly for healthcare systems.
“Talk to anyone living with a chronic disease like diabetes and they will mention the struggle of having to inject themselves – in some cases – even multiple times a day. There is a need for innovative solutions that can make treatments more accessible and less invasive for people that live with chronic conditions,“ says Exolvo co-founder and CEO, Brian Longstreet.
Exolvo Biosciences is a biotech company that aims to transform the oral delivery of large, complex molecules.
Using Verily’s technology, Exolvo aims to transform biological drug delivery to make treatments more accessible and less invasive.
Exolvo’s technology is making progress towards assembling an IND (Investigational New Drug) package in the U.S. while simultaneously actively engaging with key pharmaceutical and biotech partners.
NLC Health Ventures: Active health technology investor
Based out of Amsterdam, NLC Health Ventures is the most active health technology investor in Europe and the world’s largest healthtech venture builder.
NLC finds, builds, and scales transformative health innovations to provide more patients with quality care.
NLC is ‘BCorp,’ its funds comply with SFDR9 guidelines, and they contribute to ESG 3, 9, and 17.
With more than 100 startups, 4 funds, and activity in 16 countries, they bring impactful innovations to patients on a large scale.
The NLC Health Impact Fund is NLC’s newest and largest fund to date, investing in NLC’s startups. The fund deploys capital for ventures at various stages, providing both initial and follow-up funding.
01
Empowering Ukrainian Startups: Highlights from the PowerUp Ukraine 2024 Conference